We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We may also share information about your use of our site with our social media, advertising and analytics partners. Read more about our Privacy Policy.

I got it!

CNS Orphan Diseases -

the alternative route in CNS

The challenges of drug development in CNS are well known with the recent failures of the large phase III trials in Alzheimer's disease illustrating the problem. There is however an alternative route in CNS which can prove to be more accessible to small and medium sized companies, and that is CNS Orphan diseases. Diseases such as Progressive Supranuclear Palsy (PSP), Fronto-Temporal Dementia (FTD) or Huntington's disease can be initial substitutes for the likes of Alzheimer's disease or Parkinson's disease in which to test the effectiveness of a drug. This timely masterclass will assess the latest challenges and potential advantages of developing drugs in CNS Orphan diseases, compared to larger CNS indications and also looks at the support that is available to drug developers in orphan diseases. Furthermore, case studies of drug companies who have followed this route will be reviewed and lessons learnt will be drawn from them to assist you with developing your own strategies. Tel: +44 (0) 20 7827 6736 

When

9 Apr 2013 @ 08:30 am

9 Apr 2013 @ 12:30 pm

Duration: 4 hours


Where

Holiday Inn Bloomsbury

48 Coram Street

Greater London

United Kingdom


Organised by

SMi Group Ltd.

Similar Events in Science

BioFIT 2020

France, 7 Dec 2020

Similar Webinars in Science

Recent Publications in Science

Recent Videos in Science

Recent News in Science

Which are Europe’s most creative cities? Find out whether they’re on your path this summer – take a look at the cul… https://t.co/a0vqG3z8WK

@EU_ScienceHub - 14 Aug 2020 18:09

Wish to up-skill as a lifelong learning educator? Challenge yourself to embed entrepreneurial competences in your d… https://t.co/MJsOtxwPJZ

@EU_ScienceHub - 14 Aug 2020 16:48

Extremely valuable contribution by our 🇪🇺 colleagues, @VladimirSucha @DavidMair4 @CairneyPaul & other experts 💡 𝐒𝐜… https://t.co/eoZEQUD2O3

@EU_ScienceHub - 14 Aug 2020 14:27

Recent Speakers in Science